Icatibant Piramal Critical Care

Icatibant, the active ingredient in Icatibant Piramal Critical Care, is a bradykinin B2 receptor antagonist presented as a sterile injectable solution for subcutaneous use. It treats acute attacks of hereditary angioedema in patients who experience recurrent swelling episodes.

GNH USA supplies Icatibant Piramal Critical Care as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Icatibant is used to treat hereditary angioedema by blocking the bradykinin pathway that causes swelling.

- Acute attacks of hereditary angioedema type I: provides rapid reduction of edema and associated pain. - Acute attacks of hereditary angioedema type II: provides rapid reduction of edema and associated pain. - Acute attacks of hereditary angioedema with normal C1‑inhibitor: offers symptom relief and helps restore airway patency.

Icatibant may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling at injection site: localized erythema or edema. - Nausea: transient feeling of queasiness. - Headache: mild to moderate head pain. - Dizziness: brief sensation of lightheadedness.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Hypotension: sudden drop in blood pressure that may cause fainting. - Angioedema of the face or throat: swelling that can compromise airway. - Thrombocytopenia: low platelet count observed in rare cases.

When prescribing Icatibant, clinicians should observe several precautionary measures to ensure patient safety. - Assess hypersensitivity: verify no known allergy to icatibant or formulation components. - Monitor airway: observe for signs of airway obstruction during acute attacks. - Use with caution in cardiovascular disease: watch for hypotension or arrhythmias. - Consider renal/hepatic impairment: dose adjustment may be required in severe dysfunction. - Pregnancy and lactation: safety has not been established; avoid unless benefit outweighs risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that influence the bradykinin system or cardiovascular function.

Major Interactions (Avoid): - ACE inhibitors: increase bradykinin levels and may reduce icatibant efficacy. - Neprilysin inhibitors: elevate bradykinin and could diminish therapeutic effect. - Estrogen‑containing oral contraceptives: may exacerbate angioedema risk.

Moderate Interactions (Monitor Closely): - Other bradykinin B2 receptor antagonists: additive pharmacodynamic effects. - Diuretics: monitor blood pressure for additive hypotensive effect. - NSAIDs: may increase risk of edema or hypersensitivity reactions.